CLEAR Outcomes
2023
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
In 13,970 statin-intolerant patients, bempedoic acid reduced major adverse cardiovascular events compared with placebo.
Result
Efficacy: CV death, MI, stroke or coronary revascularisationHR 0.87
Below 1 favours bempedoic acid, above 1 favours placebo.
- Absolute difference
- 1.6 points
The absolute difference is derived from the event rates.
Also reported: No new-onset diabetes; gout and tendon-rupture signals.
- Subtopic
- Non-statin LDL
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Nissen SE, et al. N Engl J Med. 2023;388(15):1353-1364.doi 10.1056/NEJMoa2215024
Discussion & critique
Provides an outcomes-proven non-statin oral option for the genuinely statin-intolerant. The effect size is modest; the primary-prevention subgroup did better.